Reduction of hair growth

Abstract

Mammalian hair growth is reduced by applying an agonist of farnesoid X receptor.

1 . A method of reducing mammalian hair growth which comprises
 selecting an area of skin from which reduced hair growth is desired; and   applying to said area of skin a dermatologically acceptable composition comprising an agonist of farnesoid X receptor in an amount effective to reduce hair growth,   wherein said agonist is not a carbamate or ester of α-difluoromethylornithine and farnesol.   
   
   
       2 . The method of  claim 1 , wherein said agonist is a bile acid. 
   
   
       3 . The method of  claim 1 , wherein said agonist is an analog of a bile acid. 
   
   
       4 . The method of  claim 1 , wherein said agonist is a derivative of a bile acid. 
   
   
       5 . The method of  claim 1 , wherein said agonist interacts strongly with the farnesoid X receptor. 
   
   
       6 . The method of  claim 1 , wherein said agonist is lithocholic acid. 
   
   
       7 . The method of  claim 1 , wherein said agonist is cholic acid. 
   
   
       8 . The method of  claim 1 , wherein said agonist is deoxycholic acid. 
   
   
       9 . The method of  claim 1 , wherein said agonist is chenodeoxycholic acid. 
   
   
       10 . The method of  claim 1 , wherein said agonist is ursodeoxycholic acid. 
   
   
       11 . The method of  claim 1 , wherein said agonist is 6-alpha-ethyl chenodeoxycholic acid. 
   
   
       12 . The method of  claim 1 , wherein said agonist is a farnesoid. 
   
   
       13 . The method of  claim 1 , wherein said agonist is an analog of a farnesoid. 
   
   
       14 . The method of  claim 1 , wherein said agonist is a derivative of a farnesoid. 
   
   
       15 . The method of  claim 1 , wherein said agonist is farnesol. 
   
   
       16 . The method of  claim 1 , wherein said agonist is farnesal. 
   
   
       17 . The method of  claim 1 , wherein said agonist is farnesyl acetate. 
   
   
       18 . The method of  claim 1 , wherein said agonist is farnesoic acid 
   
   
       19 . The method of  claim 1 , wherein said agonist is methyl farnesyl ether. 
   
   
       20 . The method of  claim 1 , wherein said agonist is methyl farnesoate. 
   
   
       21 . The method of  claim 1 , wherein said agonist is ethyl farnesyl ether. 
   
   
       22 . The method of  claim 1 , wherein said agonist is ethyl farnesoate. 
   
   
       23 . The method of  claim 1 , wherein said agonist is 7-methyl-9-(3,3-dimethyloxivanyl)-3-methyl-2,6-nonadienoic acid methyl ester (juvenile hormone III). 
   
   
       24 . The method of  claim 1 , wherein said agonist is 7-methyl-9-(3,3-dimethyloxivanyl)-3-methyl-2,6-nonadienoic acid ethyl ester. 
   
   
       25 . The method of  claim 1 , wherein said agonist is 3alpha,7alpha-dihydroxy-6alpha-ethyl-5p-cholan-24-oic acid. 
   
   
       26 . The method of  claim 1 , wherein said agonist is 3alpha,7alpha-dihydroxy-6alpha-propyl-5p-cholan-24-oic acid. 
   
   
       27 . The method of  claim 1 , wherein said agonist is 3alpha,7alpha-dihydroxy-6alpha-allyl-5p-cholan-24-oic acid. 
   
   
       28 . The method of  claim 1 , wherein said agonist is benzenesulfonamide, N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-. 
   
   
       29 . The method of  claim 1 , wherein said agonist is benzoic acid, 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]-. 
   
   
       30 . The method of  claim 1 , wherein said agonist is phosphonic acid, [[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-, tetraethyl ester. 
   
   
       31 . The method of  claim 1 , wherein said agonist is phosphonic acid, [2-[3,5-bis(1-dimethylethyl)-4-hydroxyphenyl]ethylidene]bis-, tetrakis(1-methylethyl) ester. 
   
   
       32 . The method of  claim 1 , wherein said agonist is phosphonic acid, [2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethylidene]bis-, tetraethyl ester. 
   
   
       33 . The method of  claim 1 , wherein said agonist is phosphonic acid, [[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-, tetrakis(1-methylethyl) ester. 
   
   
       34 . The method of  claim 1 , wherein the concentration of said agonist in said composition is between 0.1% and 30%. 
   
   
       35 . The method of  claim 1 , wherein the composition provides a reduction in hair growth of at least 30% when tested in the Human Hair Follicle assay. 
   
   
       36 . The method of  claim 1 , wherein the agonist is applied to the skin in an amount of from 10 to 3000 micrograms of said agonist per square centimeter of skin. 
   
   
       37 . The method of  claim 1 , wherein said area of skin is on the face of a human. 
   
   
       38 . The method of  claim 37 , wherein the composition is applied to the area of skin in conjunction with shaving. 
   
   
       39 . The method of  claim 1 , wherein said area of skin is on a leg of the human. 
   
   
       40 . The method of  claim 1 , wherein said area of skin is on an arm of the human. 
   
   
       41 . The method of  claim 1 , wherein said area of skin is in an armpit of the human. 
   
   
       42 . The method of  claim 1 , wherein said area of skin is on the torso of the human. 
   
   
       43 . The method of  claim 1 , wherein said hair growth comprises androgen stimulated hair growth. 
   
   
       44 . The method of  claim 1 , wherein the composition further includes a second component that also causes a reduction in hair growth. 
   
   
       45 . A method of reducing mammalian hair growth, which comprises
 selecting an area of skin including hair follicles from which reduced hair growth is desired; and   applying to the area of skin a dermatologically acceptable composition comprising a compound selected from the group consisting of bile acids, bile acid analogues, and bile acid derivatives in an amount effective to reduce hair growth.   
   
   
       46 . A method of reducing mammalian hair growth, which comprises
 selecting an area of skin including hair follicles from which reduced hair growth is desired; and   applying to the area of skin, in an amount effective to reduce hair growth, a dermatogically acceptable composition comprising a compound, other than a carbamate or ester of α-difluoromethylomithine and farnesol, selected from the group consisting of compounds that increase the formation of FXR-RXR heterodimer, compounds that promote coactivator recruitment and interaction with FXR-RXR, and compounds that increase the expression of farnesoid X receptor.   
   
   
       47 . A method of reducing mammalian hair growth, which comprises
 selecting an area of skin from which reduced hair growth is desired; and   applying to the area of skin a dermatologically acceptable composition comprising a compound selected from the group consisting of farsenoids, analogues of farsenoids, and derivatives of farsenoids in an amount effective to reduce hair growth.   
   
   
       48 . A method of treating an area of exfoliated skin, comprising applying an agonist of farnesoid X receptor to the area of exfoliated skin. 
   
   
       49 . The method of  claim 48 , wherein the area of exfoliated skin has been shaved prior to application of the agonist of farnesoid X receptor.